TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announced a $3 million custom integration pipeline that includes ten active projects across its SteraMist Integrated System (SIS) and Custom Engineered System (CES) platforms. The pipeline is slated for completion by the end of 2025, with a few initiatives extending into 2026.
The new work is driven by partnerships with enclosure manufacturers—ESCO Micro Pte. Ltd., Steelco S.p.A., Pharma Biotech System Components (PBSC), Nuaire, Inc., and Getinge AB—allowing TOMI to embed its ionized hydrogen peroxide (iHP) technology directly into cleanroom and bioprocessing enclosures. The result is a turnkey, residue‑free decontamination solution that meets the stringent regulatory requirements of the life‑sciences market.
TOMI’s Q3 2025 revenue was $2 million, a 24% decline year‑over‑year, and the company posted a net loss of $450,000. The $3 million pipeline represents a 150% increase in projected future revenue relative to the current quarterly top line and signals a strategic pivot toward high‑margin recurring service and integration income. The pipeline’s value is especially noteworthy given the company’s recent revenue contraction and the need to diversify beyond capital‑equipment sales.
Chief Operating Officer Elissa J. Shane said the manufacturer relationships “drive our SIS platform strategy forward” and that the projects “represent more than transactions; they’re building blocks for sustained growth.” CEO Dr. Halden Shane added that the company’s recurring BIT™ Solution sales are expanding, citing a 95% sequential revenue increase in Q3 2025 as evidence of the strategy’s effectiveness.
Shares of TOMZ rose 8% in pre‑market trading after the announcement, reflecting investor enthusiasm for the pipeline’s potential to accelerate the company’s transition to a recurring‑revenue model and the strength of its new partnerships.
The pipeline’s completion timeline—most projects by year‑end, with some extending into 2026—highlights both momentum and the need for continued execution. Headwinds include macro‑economic uncertainty that has slowed capital‑expenditure decisions, while tailwinds such as growing demand for clean manufacturing and FDA approvals for iHP use support the company’s long‑term prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.